comparemela.com

Latest Breaking News On - University college london cancer - Page 1 : comparemela.com

Pfizer elevates Chris Boshoff to head R&D in organizational shakeup

Boshoff previously oversaw clinical research and product development activities for Pfizer’s oncology portfolio.

United statesWilliam paoMikael dolstenChris boshoffAlbert bourlaUniversity college london cancer institutePfizer research developmentOncology researchChief oncology researchDevelopment officerUniversity college london cancerChief scientific officerPfizer research

Carlos Martínez, biologist: We want to corner cancer in an evolutionary dead end | Science & Tech

The Spanish researcher from University College London took part in a macro-study that applies the theory of evolution to the fight against tumors

United kingdomCharles swantonSarah jonesCarlos martHarold varmusUniversity of valencia spainUniversity college london cancer instituteResearcher carlos martUniversity college london cancer

Bond villain DNA could transform cancer treatment, scientists say | Cancer research

Discovery that extrachromosomal DNA act as cancer-causing genes seen as breakthrough that could lead to new therapies

United statesUnited kingdomCity ofMariam jamal hanjaniCharlie swantonPaul mischelHoward changCancer research united kingdomUs national cancer instituteFrancis crick instituteUniversity college london cancer instituteProfessor paul mischelCancer grand challengesProfessor charlie swantonUniversity college london cancer

High-Dose MTX Does Not Reduce CNS Relapse in Pediatric ALL

The UKALL2011 study also showed that a shorter course of dexamethasone did not reduce toxicities, and that monthly pulses of vincristine/dexamethasone don t reduce bone marrow relapse.

United statesUnited kingdomCity ofAjay voraCynthiae dunbarMikkael sekeresAmya kirkwoodNational cancer instituteTranslational stem cell biology branchSylvester comprehensive cancer centerBlood institute in bethesdaUniversity of miami miller school medicineAmerican society of hematologyCancer research united kingdomNational heartUniversity college london cancer institute

Janssen Submits Marketing Authorisation Application to EMA Seeking Approval of Niraparib and Abiraterone Acetate Dual Action Tablet Plus Prednisone for the Treatment of Patients with HRR Gene-Mutated Metastatic Castration Resistant Prostate Cancer

The submission to the European Medicines Agency is based on results from the Phase 3 MAGNITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisonefor the treatment of

United statesLaura coughlanGerhardt attardKiran patelMathai mammenZejula smJanssen biotech incTesaro incJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonJanssen cilag internationalInternational agency for research on cancerEuropean unionClinical developmentNone of the janssen pharmaceutical companies

vimarsana © 2020. All Rights Reserved.